TipRanks (Fri, 24-Apr 6:30 AM ET)
Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers
TipRanks (Wed, 22-Apr 7:28 AM ET)
Globe Newswire (Fri, 17-Apr 3:10 PM ET)
New data demonstrates the unique scalability of Evaxion's AI-Immunology platform in glioblastoma
Globe Newswire (Fri, 17-Apr 3:00 PM ET)
Evaxion concludes Annual General Meeting
Globe Newswire (Thu, 16-Apr 11:30 AM ET)
Globe Newswire (Tue, 7-Apr 8:00 AM ET)
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
Globe Newswire (Mon, 30-Mar 8:00 AM ET)
Notice to convene Evaxion's Annual General Meeting
Globe Newswire (Thu, 19-Mar 9:00 AM ET)
Evaxion to present new data at AACR Annual Meeting
Globe Newswire (Tue, 17-Mar 4:30 PM ET)
Evaxion announces business update and full year 2025 financial results
Globe Newswire (Thu, 5-Mar 9:28 AM ET)
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Evaxion A/S - American Depositary Share trades on the NASDAQ stock market under the symbol EVAX.
As of April 24, 2026, EVAX stock price declined to $4.10 with 29,778 million shares trading.
EVAX has a beta of 1.90, meaning it tends to be more sensitive to market movements. EVAX has a correlation of 0.07 to the broad based SPY ETF.
EVAX has a market cap of $34.19 million. This is considered a Sub-Micro Cap stock.
Last quarter Evaxion A/S - American Depositary Share reported $0 in Revenue and -$.02 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.17.
In the last 3 years, EVAX traded as high as $462.50 and as low as $1.20.
EVAX has outperformed the market in the last year with a return of +175.2%, while the SPY ETF gained +34.6%. However, in the most recent history, EVAX shares have underperformed the stock market with its stock returning +1.5% in the last 3 month period and -0.2% for the last 2 week period, while SPY has returned +3.7% and +4.9%, respectively.
EVAX support price is $3.99 and resistance is $4.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVAX shares will trade within this expected range on the day.